FinnCap reaffirmed their corporate rating on shares of Avacta Group Plc (LON:AVCT) in a report published on Wednesday. FinnCap currently has a GBX 200 ($2.50) price target on the stock.

Separately, Numis Securities Ltd restated a buy rating on shares of Avacta Group Plc in a research report on Monday, August 1st.

Shares of Avacta Group Plc (LON:AVCT) traded down 1.44% during mid-day trading on Wednesday, reaching GBX 87.23. The company had a trading volume of 25,240 shares. Avacta Group Plc has a 1-year low of GBX 83.02 and a 1-year high of GBX 134.50. The company’s market capitalization is GBX 59.57 million. The stock’s 50-day moving average price is GBX 90.53 and its 200 day moving average price is GBX 96.33.

In other news, insider Mike Owen purchased 7,763 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The stock was purchased at an average cost of GBX 90 ($1.12) per share, for a total transaction of £6,986.70 ($8,729.01).

WARNING: This article was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The correct version of this article can be viewed at

Avacta Group Plc Company Profile

Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development.

Receive News & Stock Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related stocks with our FREE daily email newsletter.